vibostolimab TIGIT
Selected indexed studies
- Pharmacological and structural characterization of vibostolimab, a novel anti-TIGIT blocking antibody for cancer immunotherapy. (J Immunother Cancer, 2025) [PMID:40829901]
- Anti-TIGIT therapies for solid tumors: a systematic review. (ESMO Open, 2023) [PMID:36933320]
- TIGIT immune checkpoint blockade enhances immunity of human peripheral blood NK cells against castration-resistant prostate cancer. (Cancer Lett, 2023) [PMID:37414394]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies. (2024) pubmed
- Pharmacological and structural characterization of vibostolimab, a novel anti-TIGIT blocking antibody for cancer immunotherapy. (2025) pubmed
- First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer(☆). (2022) pubmed
- Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial. (2025) pubmed
- Anti-TIGIT therapies for solid tumors: a systematic review. (2023) pubmed
- TIGIT immune checkpoint blockade enhances immunity of human peripheral blood NK cells against castration-resistant prostate cancer. (2023) pubmed
- Development and evaluation of nanobody tracers for noninvasive nuclear imaging of the immune-checkpoint TIGIT. (2023) pubmed
- An Anti-TIGIT Antibody with a PD-1 Inhibitor Shows Promise in Solid Tumors. (2022) pubmed
- KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer. (2023) pubmed